The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
|
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
  • [11] Impact of use of antibody drug conjugates on the prognostic outcome of patients with HR+ve/HER2-ve MBC: Results from a real world dataset.
    Dawood, Shaheenah S.
    Hernandez, Gema
    Segovia, Alba
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [12] Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
    Dawood, S.
    Hernandez-Ibarburu, G.
    Segovia, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S396 - S397
  • [13] Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).
    Cazzaniga, Marina Elena
    Mustacchi, Giorgio
    Romagnoli, Emanuela
    Montemurro, Filippo
    Caporello, Paola
    De laurentiis, Michele
    Riccardi, Ferdinando
    Turletti, Anna
    De Angelis, Claudia
    Graziano, Vincenzo
    Livi, Lorenzo
    Del Mastro, Lucia
    Beano, Alessandra
    Garrone, Ornella
    Biganzoli, Laura
    Pronzato, Paolo
    De Placido, Sabino
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [14] Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.
    Mustacchi, Giorgio
    Pronzato, Paolo
    Arpino, Grazia
    D'Alonzo, Alessia
    Piezzo, Michela
    Natoli, Clara
    Milani, Andrea
    Bologna, Alessandra
    Blasi, Livio
    De Placido, Sabino
    Diodati, Lucrezia
    Beano, Alessandra
    Romagnoli, Emanuela
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [15] Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study.
    Mustacchi, Giorgio
    Pronzato, Paolo
    D'Alonzo, Alessia
    Mocerino, Carmela
    Romagnoli, Emanuela
    Garrone, Ornella
    Blasi, Livio
    De Laurentiis, Michelino
    Michelotti, Andrea
    Bologna, Alessandra
    Giordano, Monica
    Turletti, Anna
    Montemurro, Filippo
    De Placido, Sabino
    Natoli, Clara
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Marchetti, Paolo
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [16] Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study
    Mustacchi, Giorgio
    Beano, Alessandra
    Fabi, Alessandra
    Livi, Lorenzo
    Bernardo, Antonio
    Riccardi, Ferdinando
    Marchetti, Paolo
    Garrone, Ornella
    Diodati, Lucrezia
    Biganzoli, Laura
    Giordano, Monica
    Turletti, Anna
    Blasi, Livio
    Milani, Andrea
    Natoli, Clara
    Riemma, Marta
    D'Alonzo, Alessia
    Arpino, Grazia
    Pronzato, Paolo
    Cazzaniga, Marina E.
    CANCER RESEARCH, 2020, 80 (04)
  • [17] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.
    Cazzaniga, Marina Elena
    Pronzato, Paolo
    Schettini, Francesco
    Del Mastro, Lucia
    Riemma, Maria
    Alu, Massimiliano
    Turletti, Anna
    Giordano, Monica
    Pugliese, Palma
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    De Placido, Sabino
    Mustacchi, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Efficacy of endocrine-versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA)
    Schettini, F.
    Giuliano, M.
    Rognoni, C.
    De Placido, S.
    Arpino, G.
    Milani, M.
    Giordano, A.
    Cristofanilli, M.
    Jerusalem, G.
    Bachelot, T.
    Pistilli, B.
    De laurentiis, M.
    Venturini, S.
    Generali, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [19] Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
    Cazzaniga, Marina Elena
    Pronzato, Paolo
    Amoroso, Domenico
    Bernardo, Antonio
    Biganzoli, Laura
    Bisagni, Giancarlo
    Blasi, Livio
    Bria, Emilio
    Cognetti, Francesco
    Crino, Lucio
    De Laurentiis, Michelino
    Del Mastro, Lucia
    De Placido, Sabino
    Beano, Alessandra
    Ferrau, Francesco
    Foladore, Silva
    Forcignano, Rosachiara
    Gamucci, Teresa
    Garrone, Ornella
    Gennari, Alessandra
    Giordano, Monica
    Giotta, Francesco
    Giovanardi, Filippo
    Latini, Luciano
    Livi, Lorenzo
    Marchetti, Paolo
    Mattioli, Rodolfo
    Michelotti, Andrea
    Montemurro, Filippo
    Putzu, Carlo
    Riccardi, Ferdinando
    Ricciardi, Giuseppina
    Romagnoli, Emanuela
    Sarobba, Giuseppina
    Spazzapan, Simon
    Tagliaferri, Pierosandro
    Tinari, Nicola
    Tonini, Giuseppe
    Turletti, Anna
    Verusio, Claudio
    Zambelli, Alberto
    Mustacchi, Giorgio
    Papadimitriou, Christos
    CANCERS, 2024, 16 (01)
  • [20] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
    Cazzaniga, Marina Elena
    De Placido, Sabino
    D'Alonzo, Alessia
    Piezzo, Michela
    Natoli, Clara
    Milani, Andrea
    Bologna, Alessandra
    Alu, Massimiliano
    Turletti, Anna
    Pugliese, Palma
    Biganzoli, Laura
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    Romagnoli, Emanuela
    Pronzato, Paolo
    Mustacchi, Giorgio
    CANCER RESEARCH, 2020, 80 (04)
12345